Methenamine

GENITO URINARY SYSTEM AND SEX HORMONES

Key facts

Methenamine is an ofp drug catalogued in DrugCentral. It was first approved by the FDA in 1967. Recorded indications include Prevention of Bacterial Urinary Tract Infection and Urinary tract infectious disease.

• Approval status: ofp (first approved 1967 by the FDA).
• Indications: Prevention of Bacterial Urinary Tract Infection and Urinary tract infectious disease.
• ATC code: G04BX17 (Other urologicals).
• Molecular formula: C6H12N4; molecular weight 140.19 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Prevention of Bacterial Urinary Tract Infection
• Urinary tract infectious disease

Contraindications (53)

• Achalasia of esophagus
• Acute hepatitis
• Acute nephropathy
• Anemia
• Anemia due to enzyme deficiency
• Atony of colon
• Benign prostatic hyperplasia
• Bladder outflow obstruction
• Blood coagulation disorder
• Body fluid retention
• Breastfeeding (mother)
• Cardiovascular event risk
• Chronic heart failure
• Cirrhosis of liver
• Conduction disorder of the heart
• Deficiency of glucose-6-phosphate dehydrogenase
• Diabetes mellitus
• Disease of liver
• Disorder of autonomic nervous system
• Disorder of cardiovascular system
• Disorder of coronary artery
• Edema
• Factor II deficiency
• Fever greater than 100.4 Fahrenheit
• Gastritis
• Gastroesophageal reflux disease
• Gastrointestinal hemorrhage
• Gastrointestinal ulcer
• Glaucoma
• Glomerulonephritis
• + 23 more

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1967-07-05	FDA	—	CNTY LINE PHARMS

ATC classification

ATC code	Therapeutic hierarchy
G04BX17	GENITO URINARY SYSTEM AND SEX HORMONES › UROLOGICALS › UROLOGICALS › Other urologicals
J01XX05	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIBACTERIALS FOR SYSTEMIC USE › OTHER ANTIBACTERIALS › Other antibacterials

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Urinary tract infection	199.9
Endocarditis enterococcal	83.5
Respiratory syncytial virus test positive	74.5
Mitral valve replacement	73.7
Aortic valve replacement	55.4
Fall	45.6
Pathogen resistance	29.5
Clostridium difficile infection	28.1
Cystitis	27.5
Emotional distress	24.4
Diarrhoea	24.2
Multiple sclerosis	22.4

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Methenamine is on its molecule page.

• Molecular formula: C₆H₁₂N₄
• Molecular weight: 140.19 g/mol
• CAS number: 100-97-0
• InChIKey: VKYKSIONXSXAKP-UHFFFAOYSA-N
• PubChem CID: 4101

C1N2CN3CN1CN(C2)C3

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Methenamine used for?

DrugCentral lists the following indications for Methenamine: Prevention of Bacterial Urinary Tract Infection and Urinary tract infectious disease.

When was Methenamine first approved?

Methenamine was first approved by the FDA in 1967.

What is the chemical formula of Methenamine?

Methenamine has the molecular formula C6H12N4 and a molecular weight of 140.19 g/mol.

Sources

• DrugCentral drug card 3344 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1201104 — compound record and bioactivity
• PubChem CID 4101 — chemical identifiers
• DrugBank DB06799 — drug record
• FDA UNII J50OIX95QV — substance identity
• DailyMed: FDA labels for Methenamine — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.